Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL261172 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC7A5CA14CA12DPP4 | |
| Hydrochloric Acid SCHEMBL345942 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC7A5CA14CA12DPP4 | |
| SCHEMBL204828 | 0.97 | — | — | |
| SCHEMBL135982 | 0.97 | — | — | |
| SCHEMBL135981 | 0.97 | — | — | |
| Bromide SCHEMBL28463121 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC7A5CA14CA12DPP4 | |
| SCHEMBL2239379 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC7A5CA14CA12DPP4 | |
| Bromide SCHEMBL28463120 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC7A5CA14CA12DPP4 | |
| Ammonia Solution, Strong SCHEMBL27488505 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC7A5CA14CA12DPP4 | |
| Valine SCHEMBL9296321 | 0.91 | SLC7A5 (0.65) | SMN1; SMN2SLC7A5CA14CA12DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527399-B | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-113527399-A | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-103193669-A | nNOS-Capon uncoupling compound, preparation method and application thereof | UNIV NANJING MEDICAL | 2013-07-10 | — | — | CN | claimed |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS CO. LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-09-11 | — | — | US | disclosed |
| EP-4613282-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4613283-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4595973-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS Co. Ltd. (JP) | 2025-08-06 | — | — | EP | disclosed |
| CN-120152726-A | Cyclic peptide derivative composition for treating or preventing central nervous system injury diseases | 第一工业制药株式会社 | 2025-06-13 | — | — | CN | disclosed |
| EP-4567042-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS Co. Ltd. (JP) | 2025-06-11 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0950656-A1 | SULFONATED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5534541-A | THIOPHENE DERIVATIVES | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1996-07-09 | — | — | US | disclosed |
| US-4751299-A | Optically active β-lactams and method of their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0075160-B1 | PROCESS FOR RECOVERING A DIPEPTIDE DERIVATIVE | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1987-01-07 | — | — | EP | disclosed |
| EP-0144840-A2 | Optically active beta-lactams and method of their production | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4487717-A | PHASE SEPARATION USING ORGANIC SOLVENT | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0075160-A2 | Process for recovering a dipeptide derivative | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | DPP4 190/4885SMN1; SMN2 1166/4885SLC7A5 1866/4885 |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | BDNF, VIP, CA3 | DPP4 633/4885SMN1; SMN2 411/4885SLC7A5 795/4885 |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | TRMT1, TARBP1, RNGTT | DPP4 604/4885SMN1; SMN2 1881/4885SLC7A5 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.